NEW DELHI: The government is in talks with Johnson & Johnson regarding their single-dose vaccine and as per the plan, this vaccine will also be produced by Hyderabad’s Biological E, NITI Aayog member-health Dr V K Paul said.
The vaccine has shown strong neutralising antibody activity against the Delta (B16172) variant, with immunity lasting at least eight months, according to results of pre-print phase-III trials.
Johnson & Johnson had on Thursday announced that its single-shot Covid-19 vaccine showed promising signs of protection against the Delta variant rapidly spreading across the US and other countries.
According to the company report, the vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted to bioRxiv, a non-profit preprint server for the life sciences.
The vaccine has shown strong neutralising antibody activity against the Delta (B16172) variant, with immunity lasting at least eight months, according to results of pre-print phase-III trials.
Johnson & Johnson had on Thursday announced that its single-shot Covid-19 vaccine showed promising signs of protection against the Delta variant rapidly spreading across the US and other countries.
According to the company report, the vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted to bioRxiv, a non-profit preprint server for the life sciences.